{
    "clinical_study": {
        "@rank": "130945", 
        "arm_group": [
            {
                "arm_group_label": "under fasting condition group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single dose of ASP1941 under fasting condition"
            }, 
            {
                "arm_group_label": "before meal group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single dose of ASP1941 before meal"
            }, 
            {
                "arm_group_label": "after meal condition", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single dose of ASP1941 after meal"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to investigate the effect of food on the pharmacokinetics, the\n      pharmacodynamics and safety of ASP1941 after administration of  ASP1941 in healthy\n      non-elderly adult male subjects."
        }, 
        "brief_title": "A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy", 
            "Pharmacokinetics of ASP1941"
        ], 
        "detailed_description": {
            "textblock": "This will be a randomized, open-label, 3-way crossover design study to investigate the\n      effect of food on the pharmacokinetics, the pharmacodynamics and safety of ASP1941 after\n      administration of ASP1941 in healthy non-elderly adult male subjects. Each subject will\n      receive a single dose of ASP1941 \"under fasting condition\", \"before meal\" and \"after meal\"."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy as judged by the investigator/subinvestigator based on the results of\n             physical examinations and laboratory tests\n\n          -  Body weight ; \u226550.0 kg, <80.0 kg\n\n          -  Body Mass Index ; \u226517.6, <26.4\n\n          -  Written informed consent has been obtained\n\n        Exclusion Criteria:\n\n          -  Received any investigational drugs within 120 days before the screening assessment\n\n          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days,\n             or d components within 14 days before the screening assessment\n\n          -  Received medication within 7 days before hospital admission\n\n          -  A deviation from the assessment criteria of physical examinations or laboratory tests\n             at screening or upon admission\n\n          -  History of drug allergies\n\n          -  With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674777", 
            "org_study_id": "1941-CL-0071"
        }, 
        "intervention": {
            "arm_group_label": [
                "under fasting condition group", 
                "before meal group", 
                "after meal condition"
            ], 
            "description": "oral", 
            "intervention_name": "ASP1941", 
            "intervention_type": "Drug", 
            "other_name": "ipragliflozin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ASP1941", 
            "Food effect", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "August 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kantou", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of ASP1941", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Use Central Contact", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Area under the curve (AUC) from time 0 extrapolated to infinity (AUCinf), AUC from time of dosing to last quantifiable concentration (AUClast ), and maximum concentration (Cmax)", 
            "measure": "Pharmacokinetics (PK) profiles of ASP1941 (in plasma): AUCinf, AUClast and Cmax", 
            "safety_issue": "No", 
            "time_frame": "For 72 hours after each administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674777"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to attain Cmax (tmax) , apparent terminal elimination half-life (t1/2 )", 
                "measure": "Pharmacokinetics (PK) profiles of ASP1941 (in plasma): tmax, t1/2, apparent distribution volume, apparent body clearance", 
                "safety_issue": "No", 
                "time_frame": "For 72 hours after each administration"
            }, 
            {
                "measure": "Safety assessed by incidence of adverse event, vital signs, 12-lead ECG and laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "For 72 hours after each administration"
            }, 
            {
                "measure": "Changes in  urinary glucose excretion", 
                "safety_issue": "No", 
                "time_frame": "Before and for 72 hours after each administration"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}